Natalizumab (NZM), a humanized monoclonal IgG4 antibody to Î±4 integrins, is used to treat patients with relapsing-remitting multiple sclerosis (MS) 1,2 , but in about 6% of the cases persistent neutralizing anti-drug antibodies (ADAs) are induced leading to therapy discontinuation 3,4 . To understand the basis of the ADA response and the mechanism of ADA-mediated neutralization, 